Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than existing atypical anti-psychotics.
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than existing atypical anti-psychotics.
What's Your Reaction?
